Trial
NCT03404193
Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
M.D. Anderson Cancer Center
Collaborators
National Cancer Institute (NCI)
Condition
Acute Myeloid Leukemia
Intervention
Decitabine
Why stopped
\<75% participation
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-03-10